Cytokinetics (CYTK) Stock: Buy, Sell, or Hold?
CYTK - Cytokinetics Inc.
$62.31
0.28 (0.45%)
▲
5d:
+1.28%
30d:
-0.62%
90d:
-20.98%
BUY
MODERATE Confidence
Analysis Updated: Nov 3, 2026 12:00 AM ET
Earnings: Nov 04, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 28, 2026 at $61.28 · last confirmed Nov 3, 2026
Strength: 5.4/10
Get Alerted When CYTK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CYTK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CYTK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CYTK is currently trading at $62.31, which is considered fair relative to its 30-day fair value range of $61.44 to $64.60.
Technical Outlook: Technically, CYTK is in a strong downtrend. Immediate support is located at $60.15, while resistance sits at $64.78.
Market Sentiment: CYTK scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $107.39 (+72.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CYTK is in a strong downtrend. Immediate support is located at $60.15, while resistance sits at $64.78.
Market Sentiment: CYTK scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $107.39 (+72.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$61.44 -
$64.60
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (64/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 72.3% below Wall St target ($107.39)
- BULLISH: Bottoming setup score 64/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$61.44 -
$64.60
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$60.15
Resistance Level
$64.78
Current Trend
Strong Downtrend
Technical data as of
Nov 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.16
Wall Street Target
$107.39
(+72.3%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: November 03, 2026 9:55 PM ET
Data refreshes hourly during market hours. Next update: 10:55 PM
Data refreshes hourly during market hours. Next update: 10:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYTK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$278 | 50 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 53 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 62 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$144 | 35 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$117 | 63 BUY |
Advanced CYTK Option Strategies
Professional options setups generated by AI based on today's CYTK price and gamma walls.
